Gain extends trial of Parkinson’s treatment GT-02287 for 9 months
Gain Therapeutics has launched a nine-month extension of its clinical trial testing GT-02287 as a Parkinson’s disease treatment. More than half of the patients who received GT-02287 for about three months as part of the Phase 1b clinical trial (NCT06732180), which is expected to be completed at…